Nsaid Induced Gastric Ulcer — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for nsaid induced gastric ulcer. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2036. Daily refresh.

1
Approved drugs
2
Active US patents
49/100
Avg vulnerability
—
Annual revenue covered

Originators in Nsaid Induced Gastric Ulcer

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Takeda) 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating nsaid induced gastric ulcer. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Prevacid
lansoprazole
 Generic (originally Takeda) 2 49 — 2036-04-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11986554 Prevacid formulation 55 2036-04-21
11077055 Prevacid formulation 42 2036-04-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11077055 Prevacid formulation 42 2036-04-21
11986554 Prevacid formulation 55 2036-04-21

Related